Skip to content

Registry Study of RESTORE DEB Paclitaxel Releasing PTCA Balloon Catheter in China

Evaluation on the Efficacy and Safety of RESTORE Drug-Coated Balloon in Coronary Artery Disease: a Real-World Multicenter Registry Study in China

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047102
Enrollment
Unknown
Registered
2021-06-08
Start date
2021-07-15
Completion date
Unknown
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery stenosis

Interventions

RESTORE DEB paclitaxel releasing PTCA balloon catheter group:Nil

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Subjects must be at least 18 years of age; 2.Subjects participate in this study voluntarily and sign the informed consent form; 3.The authors suggest that RESTORE DEB Paclitaxel Releasing PTCA Balloon Catheter is suitable for patients with coronary artery restenosis or primary coronary artery disease.

Exclusion criteria

Exclusion criteria: 1.Life expectancy less than 2 years; 2.Patients with known contraindications to PCI or DCB: (1)Known to be allergic to any component of the drugs or research devices necessary for the operation, such as aspirin, clopidogrel, heparin, contrast agent, ticagrelor, bivalirudin, paclitaxel, shellac ammonium salt; (2)The subjects had bleeding tendency, active peptic ulcer, history of cerebral hemorrhage or subarachnoid hemorrhage, and stroke within the past 6 months; (3)Unprotected left main artery lesions or CTO lesions; (4)Pregnant, unable to exclude pregnant or nursing subjects. 3.Subject is currently participating in another clinical study of drugs or medical devices; 4.Subject is unsuitable for the study according to the investigator.

Design outcomes

Primary

MeasureTime frame
target lesion failure;cardiac death;target vessel myocardial infarction;ischemic-driven target lesion revascularization;stent thrombosis;

Secondary

MeasureTime frame
rate of device success during the procedure;rate of all-cause death;incidence rate of myocardial infarction;target vessel revascularization;target lesion revascularization;target lesion failure;patient-oriented composite endpoint;Bleeding Academic Research Federation (BARC) level 2, 3, 5 bleeding events;stent thrombosis;

Countries

China

Contacts

Public ContactJi Fusui

Beijing Hospital

jifusui@126.com+86 13701120939

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026